US equities |
MU $914.13 ▲+0.00% SNDK $1,403.34 ▲+0.00% SKHY $147.55 ▲+0.00% NVDA $221.30 ▲+0.00% TSM $430.00 ▲+0.00% SPCX $152.16 ▲+0.00% INTC $98.00 ▼-0.12% AMD $570.82 ▲+0.00%
FinancialContent

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

1.730 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment 
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human Testing Trispecifics Combine Three Complementary Cancer-Fighting Functions in... 
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
Via ACCESS Newswire
News headline image
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Via ACCESS Newswire
News headline image
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Via ACCESS Newswire
News headline image
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Aptevo Provides State of the Business Report and 2025 Financial Results
Via ACCESS Newswire
News headline image
Aptevo to Participate in March 2026 Conferences
Via ACCESS Newswire
News headline image
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Via ACCESS Newswire
News headline image
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Via ACCESS Newswire
News headline image
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
Via ACCESS Newswire
News headline image
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
Via ACCESS Newswire
News headline image
TOMI Environmental Solutions (NASDAQ: TOMZ): The Next Era of Disinfection Technology – More Stocks Inside
Via AB Newswire
News headline image
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Via ACCESS Newswire
News headline image
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
Via ACCESS Newswire
News headline image
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Via ACCESS Newswire
< Previous 1 2 3 4 Next >